RxDoctor Payments Data

Ravi Vallabhan, MD

Interventional Cardiology · Dallas, TXNPI 1184672602

Payments from drug & device makers

$88,357in general payments, 2019–2025

Across 361 payments — averaging $244.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$81K
  • Edwards Lifesciences$4K
  • Boston Scientific$829
  • AstraZeneca$699
  • Shockwave Medical, Inc$674
  • Abiomed$179
  • plus $1K from 22 others

What the payments were for

  • Speaking & faculty fees$15,00057%
  • Food & beverage$11,08642%
  • Education$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,357 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$347,497
Medicare patients
758
Services billed
7,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$423,775
Repatha SureclickEvolocumab199$167,183
XareltoRivaroxaban127$132,292
FarxigaDapagliflozin Propanediol93$86,743
EntrestoSacubitril/Valsartan80$82,042
Praluent PenAlirocumab27$23,632
JardianceEmpagliflozin15$12,917
Repatha SyringeEvolocumab11$8,936
Metoprolol Succinate522$8,125
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,119
Ezetimibe205$5,180
VascepaIcosapent Ethyl23$5,061
Rosuvastatin Calcium366$4,699
Flecainide Acetate59$4,160
Icosapent Ethyl18$4,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$423,775409 claims
AstraZenecaFarxiga$699$86,74393 claims
NovartisEntresto$100$82,04280 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →